MedTrace Logo

Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer

NCT00004062 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2013-12-19

No results posted yet for this study

Summary

RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine.

PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer.

Conditions

Interventions

DRUG

azacitidine

DRUG

liothyronine sodium

RADIATION

iodine I 131

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Lucille P. Markey Cancer Center at University of Kentucky

    lead OTHER

Principal Investigators

  • Kenneth Ain, MD · Lucille P. Markey Cancer Center at University of Kentucky

Study Design

Purpose
TREATMENT

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-07-31
Completion
2006-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004062 on ClinicalTrials.gov